DMTs During Pregnancy in Women with MS Do Not Affect Relapse Rates in Postpartum Periods
In this MEDtalk, Lene von Kappelgaard answers the question, does disease-modifying therapy during pregnancy affect the relapse rate in the postpartum period in women with MS? At ECTRIMS 2024, she presents her study aimed at exploring whether using DMTs during pregnancy affects postpartum relapse rates, especially those receiving fertility treatments, compared to pre-pregnancy or pregnancy periods.
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in